** Brokerage Leerink Partners downgrades diagnostic company Quanterix QTRX.O to "market perform" from "outperform", citing amended deal with Akoya AKYA.O "still distracts from core" and creates challenges in the market
** Brokerage also lowers PT to $8 from $12, a 32.2% upside to the stock's last close
** Brokerage doubts QTRX can successfully integrate AKYA while dealing with its own supply-chain and tariff issues
** AKYA's spatial proteomics business is in a "soft patch" in the market, with 15% revenue drop in 2024, posing an additional challenge for QTRX - Leerink
** Adds that QTRX faces another challenge as "tariff risk is modest" but still requires them to reassess and adjust their supply chain amid trade uncertainty
** Says QTRX faces "pressures in their core academic markets" and "pharma pullback in funding"
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.